Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N300

UPID:
SVBP_HUMAN

ALTERNATIVE NAMES:
Coiled coil domain-containing protein 23

ALTERNATIVE UPACC:
Q8N300; A8K5P1; D3DPW7

BACKGROUND:
The Small vasohibin-binding protein, known alternatively as Coiled coil domain-containing protein 23, is integral to mitotic spindle function and chromosome segregation. It enhances VASH1 and VASH2's tyrosine carboxypeptidase activity, facilitating alpha-tubulin's C-terminal tyrosine residue removal. This process is essential for maintaining mitotic spindle integrity and positioning. The protein also plays a role in axon and synapse formation and increases VASH1 and VASH2 solubility and secretion.

THERAPEUTIC SIGNIFICANCE:
Given its association with a neurodevelopmental disorder featuring intellectual disability, microcephaly, ataxia, and hypotonia, the therapeutic potential of the Small vasohibin-binding protein is significant. Exploring its biological mechanisms could lead to groundbreaking therapies for this and possibly other neurodevelopmental conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.